Moderna chief executive Stéphane Bancel said early data suggests the bivalent shot could provide more long-lasting protection against variants of concern than the company’s original formula alone.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,